Harvard Bioscience (HBIO) Research & Development (2010 - 2026)

Harvard Bioscience (HBIO) has reported Research & Development for 17 consecutive years, with $5.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Research & Development rose 18.97% year-over-year to $5.4 million in Q2 2026; TTM through Jun 2026 was $20.4 million, a 0.09% change from a year earlier, with the FY2025 full-year figure at $19.2 million, down 13.49% from the prior year.
• Research & Development was $5.4 million for Q2 2026 at Harvard Bioscience, up from $5.3 million in the prior quarter.
• Over five years, Research & Development peaked at $6.7 million in Q1 2022 and troughed at $4.5 million in Q2 2025.
• A 5-year average of $5.6 million and a median of $5.6 million in 2023 frame the typical range for Research & Development.
• The widest YoY moves for Research & Development: up 24.16% in 2022, down 19.0% in 2022.
• Over 5 years, Research & Development stood at $5.9 million in 2022, then climbed by 3.77% to $6.2 million in 2023, then slipped by 12.59% to $5.4 million in 2024, then retreated by 5.6% to $5.1 million in 2025, then climbed by 6.03% to $5.4 million in 2026.
• The last three Research & Development figures came in at $5.4 million (Q2 2026), $5.3 million (Q1 2026), and $5.1 million (Q4 2025), per Business Quant data.